Extracellular ATP Induces a Distorted Maturation of Dendritic Cells and Inhibits Their Capacity to Initiate Th1 Responses1

Dendritic cells (DCs) express functional purinergic receptors, but the effects of purine nucleotides on DC functions have been marginally investigated. In this study, we report on the ability of micromolar concentrations of ATP to affect the maturation and Ag-presenting function of monocyte-derived DCs in vitro. Chronic stimulation (24 h) of DCs with low, noncytotoxic ATP doses increased membrane expression of CD54, CD80, CD86, and CD83, slightly reduced the endocytic activity of DCs, and augmented their capacity to promote proliferation of allogeneic naive T lymphocytes. Moreover, ATP enhanced LPS- and soluble CD40 ligand-induced CD54, CD86, and CD83 expression. On the other hand, ATP markedly and dose-dependently inhibited LPS- and soluble CD40 ligand-dependent production of IL-1α, IL-1β, TNF-α, IL-6, and IL-12, whereas IL-1 receptor antagonist and IL-10 production was not affected. As a result, T cell lines generated from allogeneic naive CD45RA+ T cells primed with DCs matured in the presence of ATP produced lower amounts of IFN-γ and higher levels of IL-4, IL-5, and IL-10 compared with T cell lines obtained with LPS-stimulated DCs. ATP inhibition of TNF-α and IL-12 production by mature DCs was not mediated by PGs or elevation of intracellular cAMP and did not require ATP degradation. The inability of UTP and the similar potency of ADP to reproduce ATP effects indicated that ATP could function through the P2X receptor family. These results suggest that extracellular ATP may serve as an important regulatory signal to dampen IL-12 production by DCs and thus prevent exaggerated and harmful immune responses.

[1]  F. Di Virgilio,et al.  The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Kenneth M. Murphy,et al.  Dendritic cell regulation of TH1-TH2 development , 2000, Nature Immunology.

[3]  L. Nguyen,et al.  Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity , 2000, The Journal of experimental medicine.

[4]  P. Ricciardi-Castagnoli,et al.  Differential effects of corticosteroids during different stages of dendritic cell maturation , 2000, European journal of immunology.

[5]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[6]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[7]  C. Albanesi,et al.  Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. , 2000, The Journal of investigative dermatology.

[8]  F. Di Virgilio,et al.  Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca(++) mobilization and actin reorganization in human eosinophils. , 2000, Blood.

[9]  C. Szabó,et al.  Inosine Inhibits Inflammatory Cytokine Production by a Posttranscriptional Mechanism and Protects Against Endotoxin-Induced Shock1 , 2000, The Journal of Immunology.

[10]  G. Chrousos,et al.  Ligand-Activation of the Adenosine A2a Receptors Inhibits IL-12 Production by Human Monocytes , 2000, The Journal of Immunology.

[11]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[12]  G. Schuler,et al.  Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto‐nucleotidases , 1999, FEBS letters.

[13]  A. Sher,et al.  The role of dendritic cells in the induction and regulation of immunity to microbial infection. , 1999, Current opinion in immunology.

[14]  V. Diehl,et al.  Expression and a role of functionally coupled P2Y receptors in human dendritic cells , 1999, FEBS letters.

[15]  Chang‐you Wu,et al.  Cholera Toxin Suppresses Interleukin (IL)-12 Production and IL-12 Receptor β1 and β2 Chain Expression , 1999, The Journal of experimental medicine.

[16]  S. Goerdt,et al.  Other functions, other genes: alternative activation of antigen-presenting cells. , 1999, Immunity.

[17]  P. Kalinski,et al.  Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.

[18]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[19]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[20]  V. Fadok,et al.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. , 1998, The Journal of clinical investigation.

[21]  S. Endres,et al.  Anti‐inflammatory activities of cAMP‐elevating agents: enhancement of IL‐10 synthesis and concurrent suppression of TNF production , 1998, Journal of leukocyte biology.

[22]  R. Voll,et al.  Immunosuppressive effects of apoptotic cells , 1997, Nature.

[23]  L. Fabbri,et al.  Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. , 1997, The Journal of clinical investigation.

[24]  F. Di Virgilio,et al.  Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. , 1997, Journal of immunology.

[25]  A. Giannetti,et al.  Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. , 1997, The Journal of clinical investigation.

[26]  M. Moser,et al.  Effect of interleukin‐10 on dendritic cell maturation and function , 1997, European journal of immunology.

[27]  D. Ferrari,et al.  Purinoceptor function in the immune system , 1996 .

[28]  H. Zimmermann,et al.  Extracellular purine metabolism , 1996 .

[29]  G. Firestein,et al.  Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.

[30]  F. Di Virgilio,et al.  An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. , 1996, Blood.

[31]  M. Moser,et al.  Glucocorticoids down‐regulate dendritic cell function in vitro and in vivo , 1995, European journal of immunology.

[32]  M. Sitkovsky,et al.  Role of Extracellular ATP and P1 and P2 Classes of Purinergic Receptors in T‐cell Development and Cytotoxic T Lymphocyte Effector Functions , 1995, Immunological reviews.

[33]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[34]  L. Aarden,et al.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production , 1995, The Journal of experimental medicine.

[35]  A. Giannetti,et al.  Epidermal Langerhans cells are resistant to the permeabilizing effects of extracellular ATP: in vitro evidence supporting a protective role of membrane ATPase. , 1993, The Journal of investigative dermatology.

[36]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[37]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[38]  L. Fabbri,et al.  Beta 2 agonists prevent Th1 development by selective inhibition of IL-12 , 1997 .

[39]  F. Di Virgilio The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. , 1995, Immunology today.

[40]  G. Burnstock,et al.  Purinoceptors: are there families of P2X and P2Y purinoceptors? , 1994, Pharmacology & therapeutics.